Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide to reduce progression of acute respiratory failure in severe COVID-19 pneumonia
2020-001513-20Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2020
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of defibrotide in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Respiratory-failure rate (RFR). Started Jun 2020; status: completed.
02
Drugs
defibrotide
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001513-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001513-20.